Diphtheria, tetanus, and pertussis. Human papillomavirus.
Source: EvaluatePharma, Evaluate, September 2018, evaluate.com; McKinsey analysis
After a period of rapid growth, vaccine sales have slowed in recent years.
Global vaccine sales,
biennial, 1997–2017E, $ billion
1
2
From Phase I to preregistration.
Source: Pharmaprojects, Pharma Intelligence by Informa, September 2018, pharmaintelligence.informa.com; McKinsey analysis
1
Defined as any vaccine that received US Food and Drug Administration approval in preceding 5 years.
Source: EvaluatePharma, Evaluate, September 2018, evaluate.com; McKinsey analysis
1
Note: “Shots on goal” = fewer vaccine candidates are advancing to clinical studies.
Source: Pharmaprojects, Pharma Intelligence by Informa, September 2018, pharmaintelligence.informa.com; McKinsey analysis
The number of infectious-disease vaccines in development has flattened.
Phase I infectious-disease vaccines in development globally,¹
2007–17, number of products
The proportion of sales from new vaccines has declined in recent years.
Global vaccines sales,
1997–2017, %
Vaccine candidates receive fewer ‘shots on goal’ relative to other biologics.
Attrition rate of programs,
% from 2007–17
